Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology, Inflammation, and Neuropathic Pain Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for FABP5 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FABP5 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Active site conformationally intact. |
View FABP5 Products |
| Gene Delivery | FABP5 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and overexpression validation. |
View FABP5 Products |
| Benchmark Ab | Anti-FABP5 Recombinant Antibody Recombinant positive control antibody for validation assays (ELISA, Flow Cytometry, Western Blot). |
View FABP5 Products |
| Validator | FABP5 siRNA Set For target knockdown verification and target specificity validation in cell-based assays. |
View FABP5 Products |
| Related Target A | FABP4 Essential counter-screening target. High homology with FABP5; selectivity is critical to avoid metabolic off-target effects. |
View FABP4 Products |
| Related Target B | FABP3 Critical safety counter-screening target. Off-target inhibition of FABP3 (heart-type) is linked to potential cardiotoxicity. |
View FABP3 Products |
| Related Target C | PPARD (PPAR delta) Downstream nuclear receptor. FABP5 directly chaperones fatty acids to PPAR delta to trigger transcriptional activation. |
View PPARD Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| FABP Subfamily Cross-Reactivity (FABP3/4/5) | Highly purified, sequence-verified FABP3, FABP4, and FABP5 proteins available for rigorous selectivity profiling. |
| Lipid-Binding Assay Interference | Endotoxin-controlled, high-purity recombinant proteins ensure minimal background interference in fluorescent displacement assays. |
| Lack of Validated Controls | Sequence-defined clinical benchmark antibodies and validated siRNA sets included for robust assay standardization. |
| Cellular Functional Verification | High-titer lentiviral particles for stable cell line generation to track intracellular fatty acid transport and PPAR signaling. |
Live FABP5 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of FABP5 (Fatty Acid Binding Protein 5) is emerging as a highly promising frontier in oncology, neuropathic pain, and dermatological disorders. As a key intracellular chaperone for long-chain fatty acids, FABP5 plays a pivotal role in reprogramming lipid metabolism, driving cancer metastasis, and promoting inflammatory signaling via the FABP5-PPARβ/δ axis. Historically viewed as a challenging "undruggable" intracellular lipid-binding pocket, the drug discovery landscape is now shifting rapidly. The current therapeutic race is dominated by highly selective small-molecule inhibitors and targeted RNA therapeutics, with lead candidates entering early clinical trials for pain management and oncology. The next wave of FABP5 drug discovery is focused on achieving extreme selectivity over other FABP family members (especially FABP3 and FABP4) to eliminate off-target metabolic and cardiac toxicities.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Artelo Biosciences, Stony Brook University | Neuropathic Pain, CIPN, Prostate Cancer | Selectivity Screening (Need high-purity FABP3, FABP4, and FABP5 proteins for binding assays) |
| siRNA / RNAi | Alnylam, Academic Institutions | Triple-Negative Breast Cancer, Psoriasis | In vitro Knockdown Validation (Need validated FABP5 siRNA sets and qPCR/WB controls) |
| Monoclonal Antibodies | Preclinical/Discovery Stage | Metastatic Cancers (Extracellular FABP5) | Epitope Mapping & Affinity (Need native-like HEK293-expressed FABP5 proteins) |